Danish Edition
2025 Meet the experts HEMATOLOGY EHA
DANSK AFTEN
Meet the experts 2025 HEMATOLOGY | EHA & DANSK AFTEN
We have summed up the worldwide newest research within hematology presented at EHA 2025.
Insights are presented by the leading experts:
AML
Carl Sandén
Justinas Daraskevicius
Anne Louise Tølbøll Sørensen
CLL
Lydia Scarfò
Paolo Ghia
Chan Cheah
Lymphoma
Malin Rasmussen
Sara Rossetti
Mats Jerkerman
Multiple Myeloma
Fredrik Schjesvold
Hanne Norseth
Frida Bugge Askeland
Dansk Aften EHA 2025
Highlights from Dansk Aften EHA in Milan
EHA highlights
BestPractice Nordic has produced a number of MEDtalks and articles in collaboration with some of the leading researchers in hematology to present new knowledge and their latest results.
ADHD Treatment medication alleviate Fatigue in Patients with Malignant Diseases show Danish Study
Fatigue after cancer and cancer treatment is a significant burden for patients. At the same time, dealing with fatigue is an unmet need for patients. In this MEDtalk from EHA 2025, Professor Henrik Frederiksen from Odense University Hospital, Denmark, presented results from a Danish trial showing that methylphenidate, also known as Ritalin, which is used to treat ADHD, has a clinically meaningful effect in reducing fatigue scores and increasing active hours—with manageable side effects
View MEDtalk here
Improved Outcomes in High-Risk MCL with
Acalabrutinib Combination Therapy /
Jan Andreasen
A post hoc analysis presented at EHA 2025 by Professor Martin Dreyling, Klinikum der Universitaet Munchen, Germany, reinforces the clinical benefit of acalabrutinib in combination with bendamustine-rituximab for patients with high-risk mantle cell lymphoma and supports the combination as a promising first-line option for elderly patients with high-risk MCL.
Read article here
The 2025 EHA Award Recipients
/ Amanda Feldballe Bernholm
The European Hematology Association (EHA) has unveiled the recipients of its 2025 awards, honoring a distinguished group of clinicians, researchers, and leaders whose contributions are shaping the future of hematology. This year’s honorees represent a broad spectrum of innovation and excellence, from groundbreaking research to transformative clinical practice.
Novel Immune Escape Pathway in AML Identified and Successfully Blocked
A newly identified immune escape mechanism in AML involves the surface marker SLAMF6, which is upregulated in approximately 60% of patients. This marker shields leukemic cells from T-cell–mediated immune responses. In this MEDtalk, Carl Sandén, Lund University, Sweden, presents preclinical data on a novel SLAMF6-blocking antibody that restores T-cell recognition and leads to potent elimination of AML cells.
View MEDtalk here
Overcoming Venetoclax Resistance
At a poster session at EHA 2025, Justinas Daraskevicius, PhD fellow at BRIC, University of Copenhagen, Denmark, presented data from a study on functional precision medicine. In this MEDtalk, he shares findings where he and his team explored a triple combination including the selective PARP1 inhibitor saruparib, demonstrating promising anti-leukemic activity both ex vivo and in vivo.
View MEDtalk here
AML
AML
Nordic AML Group Explores Optimized Regimen for AML Patients
The venetoclax (VEN) + azacytidine (AZA) combination is standard care for newly diagnosed AML patients unfit for intensive chemotherapy, but it often causes significant myelosuppression. In this MEDtalk, Anne Louise Tølbøll Sørensen, Rigshospitalet, Denmark, presents results from a Nordic phase 2 prospective multicenter trial investigating a reduced-duration venetoclax regimen. The study aims to optimize treatment by minimizing toxicity while maintaining therapeutic effect.
View MEDtalk here
Zanubrutinib Effective as FirstLine CLL/SLL Therapy Regardless of del(17p)
At EHA 2025, five-year follow-up data from the SEQUOIA study were presented, demonstrating sustained efficacy of zanubrutinib in treatment-naïve, higher-risk patients with CLL/ SLL, regardless of del(17p) status. In this MEDtalk, Professor Paolo Ghia, Università Vita-Salute San Raffaele, Milan, Italy, shares his clinical insights on the long-term data and its implications for frontline treatment strategies of patients with or without del(17p) status.
View MEDtalk here CLL
First-in-Class BTK Degrader Drives Strong Responses in R/R CLL/SLL
During EHA 2025, Professor Lydia Scarfò from San Raffaele Hospital, Milan, Italy, presented updated data from the CADANCE-101 STUDY – BTK degrader ‘BGD-16673’ on the efficacy and safety of a potential first-in-class protein degrader in patients with heavily pretreated relapsed or refractory CLL/SLL. In this MEDtalk, Professor Scarfò emphasizes the clear need for therapies with novel mechanisms of action to achieve sustained disease control.
View MEDtalk here
Sonrotoclax + Zanubrutinib Show Durable Responses in R/R CLL/SLL
In this MEDtalk Professor Chan Y. Cheah from Sir Charles Gairdner Hospital, Western Australia, presents updated data on sonrotoclax, a next-generation oral BCL-2 inhibitor with greater selectivity and potency than venetoclax, shorter half-life, and no drug accumulation. Combined with zanubrutinib, it shows high efficacy in relapsed/refractory CLL/SLL, including in high-risk patients. Professor Cheah furthermore discusses the clinical impact of the findings.
View MEDtalk here
Durable Undetectable MRD Responses with Acalabrutinib in CLL
Professor Paolo Ghia from Università Vita-Salute San Raffaele in Milan, Italy, highlights new results from the AMPLIFI study presented at EHA 2025. The study shows that acalabrutinib plus venetoclax, with or without obinutuzumab, achieves high rates of undetectable MRD in CLL patients. Patients who maintain undetectable MRD over time show promising long-term disease control and potentially a longer-term lower risk of disease progression or death.
View MEDtalk here
Lymphoma
Several Options for Frontline Treatment of MCL
In this MEDtalk Professor Mats Jerkeman from Lund University and Skåne University Hospital, Sweden, highlights several possible frontline treatment strategies in mantle cell lymphoma that incorporate BTK inhibitors. He provides his perspective on frontline treatment strategies for younger MCL patients as well as older and high-risk patients.
Tripled Cardiac Morbidity Risk After Hodgkin Lymphoma Therapy
At EHA 2025, Sara Rossetti, MD, PhD from Rigshospitalet, Denmark, presented her study on cardiac morbidity in young Hodgkin lymphoma patients in Denmark. Her research highlights a threefold increased risk of cardiac complications, especially heart failure, compared to the general population, emphasizing the need for ongoing monitoring and further research on late treatment effects.
Radiotherapy in FL Linked to Low Relapse Rates
In this MEDtalk, Malin Rasmussen, MD, Odense University Hospital, Denmark, presents real-world data from the Danish Lymphoma Registry on first-line treatment strategies in follicular lymphoma. Most patients—regardless of initial approach (radiotherapy, watch-andwait, or systemic therapy)—did not require second-line treatment. Notably, radiotherapy was linked to particularly low relapse rates, prompting discussion on whether long-term follow-up is always necessary for this subgroup.
View MEDtalk here
Lymphoma
View MEDtalk here
Lymphoma
Lymphoma
Signs of Functional Cure for MCL in 25 Years Nordic Follow-Up Study
At EHA 2025, Professor Mats Jerkeman from Lund University and Skåne University Hospital, Sweden, presented 20 years follow-up data from the Nordic MCL2 and MCL3 trials. In this MEDtalk you can hear why the results according to Mats Jerkeman raising hope that a subset particularly those under 50 years old MCL patients could be considered cured.
View MEDtalk here
Multiple Myeloma
Real-World Insights on Belantamab Mafodotin in
RRMM
In this MEDtalk, Fredrik Schjesvold, Founder and Leader of Oslo Myeloma Center, Norway, shares real-world data on belantamab mafodotin monotherapy in relapsed/refractory multiple myeloma, presented at EHA 2025. The study shows consistent efficacy and similar ocular event rates in Europe and the US. As events are mostly manageable, the findings support a more symptom-driven approach to ocular follow-up in clinical practice.
Multiple Myeloma
TG01 Shows Promise in KRAS-Mutated Myeloma
The ongoing Phase I/II TG01 study conducted at the Oslo Myeloma Center is investigating the safety, tolerability, and efficacy of TG01 vaccination in patients with KRAS or NRAS mutations and either multiple myeloma or high-risk smoldering multiple myeloma. At EHA 2025, Hanne Norseth, MD, PhD Student, Oslo Myeloma Center, Norway, presented data from the study. In this MEDtalk, she shares her insights into the results and discusses the potential of TG01 as a novel immunotherapeutic approach for this patient population.
View MEDtalk here
Multiple Myeloma
Impact of Treating MRD Relapse Post 1L in Multiple Myeloma
Frida Bugge Askeland, MD, Oslo Myeloma Center, Norway presents findings from the Norwegian REMNANT study in this MEDtalk. The study investigates whether early intervention at MRD relapse following first-line (1L) treatment can improve progression-free survival (PFS) and overall survival (OS) in patients with multiple myeloma (MM).
View MEDtalk here
Dansk Aften EHA 2025
Danish Insights from EHA 2025: Highlights from Dansk Aften
During the EHA 2025 congress in Milan, BestPractice Nordic hosted Dansk Aften EHA – a professional and social event where Danish specialists gathered to connect, reflect on, and discuss key hematological advances presented at the congress.
Tarec Christoffer El-Galaly led the evening, which featured presentations where each speaker shared key studies and data from EHA 2025 relevant to their field of expertise. The aim was to provide a clinically relevant overview of the most important new insights presented at the congress.
Tarec Christoffer El-Galaly presented key takeaways on the treatment of older patients with lymphoma, Sigrun Thorsteinsdottir summarized recent developments in multiple myeloma, Daniel Kristensen highlighted new findings in acute myeloid leukemia, and Martin Hutchings gave a thorough update on lymphoma.
The event concluded with a dinner, providing an opportunity for further discussions and networking.
We sincerely thank our sponsors for making Dansk Aften EHA possible and supporting this valuable occasion for knowledge-sharing and professional collaboration.